^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TNFRSF1A overexpression

    i
    Other names: TNFRSF1A, TNF Receptor Superfamily Member 1A, TNFAR, TNF-R-I, TNF-R55, TNFR60, CD120a, TNF-R, TNFR1, Tumor Necrosis Factor Receptor Superfamily Member 1A, TNF-R1, TNF-RI, TNFR-I, P55, P60, Tumor Necrosis Factor Receptor Superfamily, Member 1A, Tumor Necrosis Factor Binding Protein 1, Tumor Necrosis Factor Receptor Type 1, Tumor Necrosis Factor Receptor Type I, Tumor Necrosis Factor-Alpha Receptor, Tumor Necrosis Factor Receptor 1, CD120a Antigen, TNFR55, P55-R, TBP1, FPF
    Entrez ID:
    7132
    Related biomarkers:
    Expression
    Mutation
    2ms
    NPS-1034 Exerts Therapeutic Efficacy in Renal Cell Carcinoma Through Multiple Targets of MET, AXL, and TNFRSF1A Signaling in a Metastatic Model. (PubMed, Cells)
    In conclusion, we explored the therapeutic mechanism of NPS-1034 and found that it targets not only MET and AXL but also TNFRSF1A. In a lung metastatic animal model, we confirmed that NPS-1034 is a potential candidate for systemic therapy in RCC.
    Journal • IO biomarker • Metastases
    |
    AXL (AXL Receptor Tyrosine Kinase) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • GADD45A (Growth arrest and DNA-damage-inducible, alpha)
    |
    TNFRSF1A overexpression
    11ms
    Identification of TNFRSF1A as a novel regulator of carfilzomib resistance in multiple myeloma. (PubMed, Oncol Res)
    The suppression of MHC genes and cell adhesion molecules may impair the interaction between immune cells and cancer cells to impair antitumor immunity. Future studies are warranted to further investigate the signaling pathway underlying the regulatory role of TNFRSF1A in MM cells.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF1A (TNF Receptor Superfamily Member 1A)
    |
    TNFRSF1A overexpression
    |
    carfilzomib
    over1year
    TNFR1 and TNFR2, Which Link NF-κB Activation, Drive Lung Cancer Progression, Cell Dedifferentiation, and Metastasis. (PubMed, Cancers (Basel))
    Of note, TNF stimulated the activities of TNFR1 and TNFR2, two membrane-binding receptors, which accelerate tumorigenesis through diverse mechanisms. This review focuses on these new findings regarding the roles of TNFR1 and TNFR2 in lung SCC and ADC development in humans and mice, and highlights the potential therapeutic targets of human lung cancers.
    Review • Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD4 (CD4 Molecule) • SOX2 • TNFRSF1A (TNF Receptor Superfamily Member 1A) • FOXP3 (Forkhead Box P3) • TWIST1 (Twist Family BHLH Transcription Factor 1) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    |
    CD4 expression • TNFRSF1A overexpression • FOXP3 expression
    almost2years
    CD20/TNFR1 dual-targeting antibody enhances lysosome rupture-mediated cell death in B cell lymphoma. (PubMed, Cancer Immunol Immunother)
    Obinutuzumab is a therapeutic antibody for B cell non-Hodgkin's Lymphoma (BNHL), which is a glyco-engineered anti-CD20 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) and causes binding-induced direct cell death (DCD) through lysosome membrane permeabilization (LMP)...Further, OBI-TNFα blocked NF-κB activation in the presence of TNF-α, implying that it can antagonise the proliferative role of TNF-α in cancers.Our study suggests that dual targeting of CD20 and TNFR1 can be a new therapeutic strategy for improving BNHL treatment. The OBI-TNFα fusion protein enhances DCD and ADCC and prevents the proliferating effect of TNFα signalling; therefore, it may provide precision treatment for patients with BNHL, especially those with upregulated TNFR1 expression.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF1A (TNF Receptor Superfamily Member 1A)
    |
    TNFRSF1A overexpression
    |
    Gazyva (obinutuzumab)
    2years
    A TNFR1-UBCH10 axis drives lung squamous cell carcinoma dedifferentiation and metastasis through a cell-autonomous signaling loop. (PubMed, Cell Death Dis)
    These findings demonstrate that an overexpressed TNFR1-UBCH10 axis advances lung carcinogenesis and metastasis through a dedifferentiation mechanism. Constituents in this pathway may contribute to the development of differentiation-related therapies for lung SCC.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • SOX2 • TNFRSF1A (TNF Receptor Superfamily Member 1A) • TWIST1 (Twist Family BHLH Transcription Factor 1) • KRT5 (Keratin 5) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    |
    BCL2 expression • MYC expression • SOX2 expression • TNFRSF1A overexpression
    over2years
    IL-17 SIGNALING REGULATES TNFRI-CASPASE2-SREBP1/2-DHCR7-MEDIATED DE NOVO LIPOGENESIS AND TUMORIGENESIS IN ALCOHOL-INDUCED LIVER DISEASE IN MICE (DDW 2022)
    TNFR1 and DHCR7 are key downstream targets of IL-17 signaling. Inhibiting IL-17 signaling in metabolically injured hepatocytes may provide a new strategy to treat alcohol-induced fibrosis and HCC.
    Preclinical
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • IL17A (Interleukin 17A) • IL17RA (Interleukin 17 Receptor A) • ERN1 (Endoplasmic Reticulum To Nucleus Signaling 1) • DHCR7 (7-Dehydrocholesterol Reductase)
    |
    TNFRSF1A overexpression